Special Therapies · Vivecura Berlin

Ketamine-Assisted Therapy: Hope for Treatment-Resistant Mental Health Conditions

What the science actually says, and why the setting matters more than the substance.

Imagine a medication that works in hours.

Not in six weeks. In hours.

A medication that, in clinical studies of people with treatment-resistant depression, has reached response rates of up to 50%, even when two or more antidepressants had previously failed. A medication that may reduce suicidal thoughts within hours, before any conventional therapy has even begun to work.

And still many people have never seriously heard of it.

Many people hear the name ketamine and immediately think: party drug. Anesthetic. Risk of dependence. These questions are understandable, and they are important. Because exactly here begins the real misunderstanding.

Between the operating theater and the party basement, there is a third space. A medical, therapeutic space. A space in which ketamine does not numb, but can open something. And exactly that is the difference between a crash and healing.

If you want to know directly whether this is relevant for you At the end of this article you will find a self-check, an overview of indications and contraindications, and the link to book an appointment at Vivecura.

Specialty area at Vivecura: Ketamine-assisted therapy & integration

Ketamine therapy is one of my four focus areas, alongside Gut Reset, mold treatment, and heavy-metal detoxification. I do not offer this therapy out of theoretical interest. I have experienced it myself. And that experience did not only change my practice, it changed my life.

Current area Off-label, physician-supervised Integration in focus
My honest framing before you read on

Behavioral therapy is like walking on foot. Psychoanalysis is like cycling. Ketamine-assisted therapy with real integration is like driving a Ferrari. You do not just arrive at the destination, you experience the road in such a different way that your inner orientation changes forever.

All of these have their place. Sometimes walking is exactly the right thing. But sometimes a person does not need more steps, they need a different quality of experience. That is what I keep seeing with ketamine: not a shortcut, but a dimension that other forms of therapy do not have.

I am from Syria. And Germany was not home for a long time.

I am grateful for this country, I have to say that here, without qualification. Germany gave me safety when my homeland could no longer do so. It made it possible for me to study medicine, to build a practice, to live a good life despite all the difficulties. I do not forget that.

And still: at home is something I did not feel here for a long time. Safe, yes. Welcomed, yes. But that deep, quiet sense of “this is where I belong” was missing. For years. I kept thinking: maybe at some point I will leave. Maybe this is not permanently mine.

“Where is your home?” That question followed me. And no thought, no analysis, no conversation truly answered it.

In one of my ketamine sessions, which I had begun without a therapeutic agenda, simply to understand what I was actually offering my patients, I experienced something that I can still barely put into words. It was not a thought. It was a physical, emotional, image-rich experience of what home truly means.

Home is not a place. Home is a feeling on the inside that I can cultivate, regardless of where I happen to be living.

After that session I no longer wanted to leave. Not because Germany had changed, but because I had changed. I stopped expecting an external place to give me what can only arise on the inside. I started experiencing my practice in Berlin as a deliberate choice, not as a temporary stop. I stayed. Not because I had to, but because I wanted to.

The second theme: knowing and changing are two different things.

I was in psychoanalysis. Intensively. It was good. I came to understand a lot about myself, my patterns, my relationship dynamics, the structures that kept repeating in my partnership at the time. I saw what was not working. I knew the causes. I understood my pattern, intellectually and completely.

And still nothing essential changed. Not really. The head knew. The rest of me did not.

I knew my pattern. I could name it, explain it, trace it back to childhood. And I lived it anyway. Knowing and changing are two completely different things.

In the ketamine sessions, something different happened. I no longer experienced my patterns as abstract concepts, I saw them. As inner images. As scenes that unfolded before me. I felt what these patterns had done to me, how they had come about, what they had once tried to protect. Not cognitively. Holistically. Feeling, understanding, and the will to change all at once, in a single moment.

That was what had been missing. Not more analysis. Not more knowing. The experience. The difference between reading a map and actually walking the path.

After that experience, change was no longer effortful. It happened almost on its own. Not because ketamine had “healed” me, but because for the first time I had truly felt what I had only ever thought. And after the felt experience, change became almost easy.

Classical therapy

Understanding what is happening

Psychoanalysis and behavioral therapy create awareness, cognitive structures, new frames of meaning. You understand the pattern. You know how it came about. You can name it.

Between understanding and lasting change, there is often a gap that more understanding cannot close. The head knows. The rest does not.

Ketamine-assisted therapy

Experiencing what is happening

Ketamine opens a state in which old patterns can not only be analyzed, but felt, through inner images, bodily sensations, emotional truths.

Feeling, understanding, and willingness to change appear at the same time, as one whole experience. After that, change is no longer an act of will. It happens.

1. What ketamine is, and what it is not

Ketamine was developed in the early 1960s as an anesthetic, and it is still used worldwide today. In emergency rooms, in operations, in pain therapy. It belongs to the few substances that do not depress breathing, that stabilize circulation, that can be dosed extremely reliably, and that have hardly any toxic side effects when used correctly.

Then something fascinating was discovered. At a much lower dose, sub-anesthetic, it is called, ketamine can produce an almost opposite effect in depression, trauma, and chronic tension. Not numbing. But opening.

And exactly this discovery has turned the psychiatric research of the past twenty years on its head.

Anonymous. 41 years old. Architect from Berlin-Mitte. He came after years. Three different antidepressants. Two inpatient stays. Psychotherapy over years. “I do not feel depressed anymore,” he said in our first conversation. “I do not feel anything at all anymore.” That was the worst part. This leaden indifference, this nothingness. We talked about ketamine. Not as the first step, but after a thorough screening and after a long conversation about expectations, risks, and goals. After the second infusion he told me: “For the first time in years, something was there again. I do not know how to describe it. But it was there.” That is not a miracle, but it is a beginning. And sometimes you need that beginning.

2. What happens in the brain, the neurobiology in plain language

Classical antidepressants work on the serotonin or norepinephrine system. That is important and effective. But it takes weeks, sometimes months. And it does not help everyone.

Ketamine takes a different route.

The NMDA receptor: the gateway to change

Ketamine blocks a specific receptor type in the brain: the NMDA receptor, a glutamate receptor. Glutamate is the most important excitatory messenger of the brain. Imagine NMDA receptors like locks that regulate the flow of information between nerve cells. In chronic depression, these locks could be stuck in an unhealthy pattern.

When ketamine blocks these receptors, something surprising happens at first: the nerve cells are briefly freed from a certain kind of inhibition. That leads to a short-term rise in glutamate in other regions. And this rise in glutamate triggers a cascade that reaches directly into the architecture of the cell.

BDNF, mTOR, and synaptogenesis: the actual healing process

Imagine BDNF, brain-derived neurotrophic factor, as the fertilizer of the brain. Chronic stress and depression reduce BDNF, the connections between nerve cells become weaker, thinner, fewer.

Ketamine very quickly triggers an increase in BDNF synthesis. This happens through activation of the mTOR signaling pathway, a kind of cellular hub for growth signals. The result: new synaptic connections form, damaged ones are repaired. This process, which neuroscientists call synaptogenesis, was described by Krystal and colleagues in 2024 in Neuropsychopharmacology as responsible for both the rapid and the longer-lasting effects of ketamine.

Mechanism review 2024

Krystal JH, Kavalali ET, and Monteggia LM published a comprehensive overview in 2024 in Neuropsychopharmacology. The core message: ketamine’s NMDA blockade inhibits eEF2 kinase, which lifts the suppression of BDNF translation. BDNF activates TrkB receptors, which leads to rapid synaptic plasticity. At the same time, AMPA receptor stimulation activates the mTOR pathway and drives synaptogenesis. These are the rapid as well as the lasting effects.

Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50.

What does this mean for a person? In depression, the brain metaphorically receives fewer growth signals. Connections that stand for joy, hope, motivation become weaker. Ketamine can kick off this process within hours, and that is biologically unique among the antidepressants we know.

Reframe

Ketamine is not a happiness hormone. It is a growth impulse. It does not make you “happy.” For a defined period, it creates the neurobiological conditions under which change becomes possible. What happens in that window is decided in the therapeutic frame, in the integration, in the conversation afterwards. That is the difference between an experience and a healing.

3. How fast does ketamine work, and how long does it last?

This is perhaps the most fascinating part.

Classical antidepressants need six to eight weeks. Ketamine begins to act within hours. The peak of the antidepressant effect lies between 24 and 72 hours after an infusion.

This is not mysticism. It is the synaptic growth processes that begin immediately after the infusion.

Single infusion versus a series

A single infusion (0.5 mg/kg over 40 minutes) may work for many people for up to seven days. That is meaningful, but not enough for lasting change. Repeated infusions over two to three weeks can extend the effect, although the optimal number and frequency are still subjects of research.

Real-world meta-analysis

Alnefeesi and colleagues analyzed in 2022, in one of the most comprehensive reviews, 79 real-world studies with a total of 2,665 patients with treatment-resistant depression. The result: on average about 45% of patients showed a response (at least 50% symptom reduction), and about 30% reached remission. Importantly, the effect size was substantial (Hedges g = 1.44), and the effect did not fade with repeated treatment.

Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
An honest framing of the numbers

Some sources cite response rates of 50% to 80%. That is true for some controlled single studies under optimal conditions. The aggregated real-world evidence shows somewhat lower numbers: about 45% response, 30% remission. That is still extraordinarily good for a patient group that has not responded to anything else. But it is important to be honest with this: ketamine does not help everyone. And it does not heal. It can open a therapeutic space.

4. Treatment-resistant depression: when nothing else helps

I bet you know this feeling. Or you know someone who does.

Not sick enough to need a hospital, but not healthy enough to truly live. A life in gray. Medications that do nothing. Sessions that go in circles. That exhausted “I have already tried everything.”

Treatment-resistant depression is defined as the lack of improvement despite at least two adequate antidepressant treatments in the current depressive episode. This affects an estimated one in three people with severe depression.

Overview of overviews 2024

Rodolico and colleagues published in 2024 in Frontiers in Psychiatry an umbrella review of 26 systematic reviews and 44 randomized studies including more than 3,000 patients. The central finding: ketamine and its S-enantiomer esketamine consistently show a rapid, significant antidepressant effect in treatment-resistant depression. The authors note explicitly: study quality is overall low to moderate, and long-term effects are insufficiently researched. That is important. The evidence is real, but not infallible.

Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399.

What does that mean in practice? In treatment-resistant depression, ketamine can bring a noticeable relief within hours. It is not a magic remedy. But in the research it is so far the fastest and strongest tool for people for whom everything else has failed.

And what about suicidality?

This is a particularly important point. Classical antidepressants need weeks to develop anti-suicidal effects, and in the first two weeks the suicide risk can even rise briefly. Ketamine may reduce suicidal thoughts within hours, sometimes after a single infusion. Clinically, that has life-saving relevance.

5. Bipolar depression: when the dark phases will not lift

People with bipolar disorder know a particular dilemma: many medications help against mania, but barely against the deep depressive phases. And exactly in those phases lies the greatest risk.

Systematic review

Bahji, Zarate, and Vazquez published in 2021 in the International Journal of Neuropsychopharmacology a systematic review on ketamine in bipolar depression. They analyzed 6 studies with a total of 135 patients. Participants received ketamine infusions (0.5 mg/kg) in addition to a mood stabilizer. In most studies, the depressive phase improved rapidly. The risk of a manic switch was low, but present. The authors describe this as preliminary evidence that requires further research.

Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541.
Important caveat: in bipolar disorder, ketamine is not a first-line treatment, and it should only be used in close psychiatric supervision and in combination with a mood stabilizer. The risk of a manic switch is low but real. Ketamine does not replace mood-stabilizing medication.

6. PTSD: when the trauma keeps living in the nervous system

Post-traumatic stress disorder arises after extreme experiences. Violence, loss, accidents, emotional neglect. The symptoms are wearing: flashbacks, nightmares, dissociation, constant over-arousal, the sense of being cut off from oneself or from the world.

What may make ketamine particularly relevant here? Traumatic memories are deeply encoded in the nervous system. Classical therapies need time to reach those layers. Ketamine can ease access to emotionally charged content by briefly reducing cognitive control and opening access to inner experience.

First RCT of ketamine in PTSD

Feder and colleagues (2014) published in JAMA Psychiatry the first randomized controlled crossover trial of ketamine in chronic PTSD. Compared to active placebo (midazolam), a single ketamine infusion showed a significantly greater reduction of PTSD symptoms 24 hours after administration. That was a proof of concept, the first demonstration that ketamine has any effect in PTSD at all.

Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688.
PTSD meta-analysis 2024

Borgogna and colleagues (2024) summarized the available RCTs on ketamine in PTSD in a meta-analysis. Ketamine showed consistent reductions on PTSD symptom scales. The authors emphasize: ketamine works best when it is not used as pure sedation, but as a door-opener in combination with therapeutic accompaniment and integration.

Borgogna NC et al. So how special is ‘special K’? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
Honest framing, the PTSD evidence is nuanced

An important finding: Abdallah and colleagues tested in 2022, in one of the largest RCTs to date (n = 158 veterans), repeated ketamine infusions in PTSD. They found significant improvements in depression, but no significant effect on the core PTSD symptoms (PCL-5, CAPS-5). That means the evidence for ketamine in PTSD is promising, but not yet consistent. The strongest effects are seen in combination with psychotherapy.

7. Ketamine alone opens a door, therapy turns it into a room

To me, this is one of the most important points. And it is often underestimated.

Ketamine changes consciousness. It opens a window in which new perspectives can arise, in which old patterns are less rigid, in which something stuck becomes movable again. But this window closes.

What you do in that window makes the difference. That is the core of ketamine-assisted psychotherapy.

KAP systematic review 2022

Drozdz and colleagues published in 2022 in the Journal of Pain Research a systematic narrative review of the literature on ketamine-assisted psychotherapy. They showed that combining ketamine with psychotherapeutic elements before, during, and after the session consistently produces more stable and longer-lasting effects than ketamine alone. This applies in depression, PTSD, and substance-use disorders.

Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706.
Convergence study 2025

Sakopoulos and Todman describe in 2025 in the International Journal of Molecular Sciences the mechanism by which psychotherapy extends the effects of ketamine: the neuroplastic state after ketamine creates an “open phase” of heightened synaptic malleability. Psychotherapeutic interventions in that window can anchor new cognitive and emotional patterns more deeply than would be possible without this biological precondition.

Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673.

Ketamine alone is like a door that opens briefly. Without integration, you walk past it. With accompaniment, it becomes a room you can actually step into.

8. What you experience in a session

Every experience is unique. But there are recurring patterns that most people describe.

Dissociation

An observer-like sense. You perceive yourself as if you were slightly outside of yourself. That can be liberating if you usually get very stuck in your own head.

Old emotions

Things that have not had space for a long time may surface. Sometimes tears. Sometimes anger. Sometimes simply a deep exhaustion that is finally given room.

Inner images

Many describe visual or symbolic experiences. Not hallucinations in the literal sense, more like vivid dreaming with full awareness.

Body sensations

Warmth, tingling, a sense of softness or heaviness. Many experience a deep state of bodily relaxation that feels very unfamiliar.

Many people experience this as both shaking and clarifying. Sometimes something rises that has had no place for years. That can be overwhelming. But this is exactly what a safe therapeutic frame is for: not to push it away, but to say: you are allowed to be here.

9. Does ketamine cause addiction? An honest answer

I hear this question in every first conversation. And it is justified.

Ketamine is misused recreationally, often in very high doses, daily, combined with other substances. That carries real risks: psychological dependence, bladder damage (so-called ketamine cystitis), and memory problems with chronic use.

But that is a completely different setting from therapeutic use.

Risk assessment, recreational versus medical use

Morgan and Curran (2012, Addiction) showed that the negative effects of ketamine depend strongly on dose, frequency, and context. Frequent recreational use is associated with increased risk of dependence, cognitive deficits, and bladder damage. The authors classify ketamine as a substance with low to moderate physical dependence potential, considerably lower than alcohol, opioids, or benzodiazepines.

Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38.

In therapeutic use, fundamentally different parameters apply: precisely dosed single doses with long intervals between them, under medical supervision, with psychological preparation and integration. Ketamine does not cause physical withdrawal as alcohol, benzodiazepines, or opioids do.

But: psychological dependence can develop when people use ketamine to escape feelings, without therapeutic accompaniment. The opposite of the therapeutic goal. That is why the frame is decisive. The point is not to create a new attachment. The point is to become freer.

Reframe

Ketamine cystitis is real, but not relevant in therapeutic use. Bladder damage develops with daily consumption of high doses over months. That is in no way the therapeutic protocol. An infusion every few weeks under medical supervision does not carry that risk. Even so, monitoring is appropriate with repeated treatments.

10. Mechanism and clinical practice: what the neurobiology means for the experience

I would like to go one step further. Because the neurobiology explains something that many patients describe intuitively, but find hard to put into words.

In severe depression or chronic trauma, synaptic connections literally shrink. Not metaphorically. Microscopically measurable. The prefrontal cortex, responsible for perspective, planning, and emotional regulation, loses density of connections.

What ketamine sets in motion is, at its core, a regenerative process. New synaptic connections form within hours. This state of heightened neuronal plasticity, which lasts for a defined period after the infusion, is the biological window in which therapeutic work can act more deeply.

Many patients describe it like this: “My head was finally quiet. And for the first time in years, I could feel what was actually there.”

That is not suggestion. That is synaptogenesis.

11. How a treatment with me unfolds

Every person brings their own story, a different nervous system, and an individual body. That is why no treatment with me starts with an infusion. It starts with real listening.

Step 1: history and integrative diagnostics

We begin with an in-depth conversation about your life, your symptoms, previous therapies, and inner themes. This also includes physical diagnostics, because emotional state and biochemical foundations are inseparable.

What I look at

  • Nutrients: vitamin D, B12, omega-3, magnesium, zinc
  • Hormones and thyroid: including fT3, fT4, anti-TPO
  • Gut flora and inflammation markers: hsCRP, microbiome status
  • Stress system: cortisol day profile, HRV, sleep profile
  • Environmental toxins: when history points to it (mold, heavy metals)
  • Cardiovascular: particularly relevant before ketamine (blood-pressure monitoring)

Step 2: preparation and setting conversation

Before you receive ketamine, we clarify: what is your goal? What is allowed to come up? What do you need if it gets intense? This conversation is decisive. It gives your experience a safe frame.

Step 3: the infusion, precisely dosed, medically monitored

0.5 mg/kg of ketamine, slowly over about 40 minutes, intravenously. Heart rate and blood pressure are monitored continuously. Eye protection reduces external stimuli. Music carries the process emotionally. I am present the entire time.

The setting makes the difference. Ketamine can do more when the room around it is shaped properly.

Step 4: integration

After every session we talk: what did you experience? Which feelings were there? What has shifted? The experience is the impulse. Integration turns it into change.

Step 5: course and closure

After several sessions (depending on the situation, typically 4 to 6), a new inner space often emerges: more clarity, more access to feelings, more self-leadership. My goal is not for you to stay with me. My goal is that you learn to accompany yourself.

12. Why I always work integratively

Many people, when they think of mental health, think only of conversations, diagnoses, and medications. But what about a vitamin D deficiency that blocks drive and mood? About chronic inflammation that weighs on body and nervous system? About a dysbiosis in the gut that, via the gut-brain axis, dulls emotional experience?

Your emotional state has biochemical foundations. Ketamine does not treat isolated symptoms. It is part of an integrative approach that takes all levels into account.

Reframe: ketamine is not a shortcut

Ketamine does not replace diagnostic work, sleep, the shaping of relationships, or a foundation built from nutrition and movement. It is a tool within a systemic approach. Anyone who treats ketamine as a shortcut misses the decisive point: the window that ketamine opens can only be used fully when the rest of the system is also at work.

13. Who ketamine is suited for, and who it is not

Possibly suitable Treatment-resistant depression (at least 2 antidepressants without sufficient effect). PTSD, where classical therapies have not been enough. Bipolar depression in psychiatric supervision and with a mood stabilizer. People who do not just want to talk, but to experience and integrate.
Contraindications / not yet suitable Untreated or active psychosis. Active mania. Uncontrolled high blood pressure or severe cardiac disease. Active substance-use disorder without accompanying treatment. Pregnancy. A lack of willingness to prepare and integrate.
Regulatory note: esketamine (as a nasal spray, Spravato) has been authorized in the EU since December 2019 for treatment-resistant depression, and since February 2021 also for acute depressive episodes with psychiatric emergency character. Intravenous racemic ketamine remains off-label for psychiatric indications in Germany, that is, it is used without a formal authorization for this purpose, under the individual responsibility of the physician. This is legal and clinically established, but it requires transparency with patients.

Ketamine is not only for severe diagnoses.

If you have read this far, you have learned a lot about treatment-resistant depression, PTSD, and bipolar disorder. That is the scientific language in which ketamine is researched and described. But I want to be honest: that is not the full picture of what I see in my practice.

Many of the people who come to me have none of these severe diagnoses. No treatment resistance, no clinical entity that sits in a DSM category. And still they have benefited deeply from ketamine.

My personal conviction

I believe that ketamine-assisted therapy with real integration can support any person who wants to expand their consciousness, consciously turn down the thinking mind, and heal more through feeling and experiencing. That is not an exception to the medical use. That is the actual core of it.

We live in a culture that places cognitive understanding above bodily experience. We analyze, name, categorize. We know a lot about ourselves. And still little often changes. Not because we know too little, but because knowing alone is not enough. The key is in the experience, not in the understanding.

Ketamine can temporarily make the analytical part of the mind, the part that constantly judges, controls, and comments, quieter. What remains is a deeper access to what is actually going on inside us. Images, feelings, connections that do not appear in normal waking consciousness. That is not a mystical process. It is neurobiology: fewer filters, more access.

People without a clinical diagnosis, who simply had the feeling of not being quite at home in themselves. Who understood why they have certain patterns, but could not let them go. Who had already come a long way in therapy, and still felt that one layer was missing.

These people often left ketamine sessions different from how they came in. Not because something “sick” was healed. But because something that had been split off was integrated. More contact with themselves. More clarity. Less inner noise.

So please do not let the clinical language in this article put you off. If you have the feeling that pure thinking is reaching its limits, that you want to feel more and analyze less, or that you are searching for a deep experience that can spark real change from within, that is a fully valid reason for a conversation. You do not have to be ill to benefit from ketamine. You only have to be ready.

14. Self-check: could ketamine be relevant for you?

Block 1: your treatment history

  • Have you tried at least two different antidepressants in adequate dose and duration without significant improvement?
  • Are you in psychotherapy, or have you been, and notice that you are “going in circles” or not really getting through?
  • Do you have the feeling that you know what your problem is, but cannot find emotional access to it?
  • Do you have a diagnosis of PTSD, and have classical trauma therapies so far helped only a little?

Block 2: your inner readiness

  • Are you willing to let yourself enter a deeper, possibly intense inner experience?
  • Can you imagine working seriously with what comes up after a session?
  • Do you have a basic interest in what is going on inside you, beyond the symptom?
  • Are you not actively at risk of substance dependence or in an acute psychotic phase?

Please seek prompt medical care for:

  • Acute suicidality. Ketamine can be part of the solution, but it is not a substitute for acute care
  • An unclear diagnosis. Before ketamine is considered, the underlying diagnosis must be in place
  • Known cardiac disease or uncontrolled high blood pressure
  • Active psychosis or known schizophrenia
  • Pregnancy or pregnancy plans

Ketamine within the system, the connection to my other specialty areas

Mental health is rarely isolated. In my practice I regularly see this: people struggling with treatment-resistant depression or PTSD often carry a biological load at the same time, mold toxins that produce neuroinflammation, heavy metals that disrupt neurotransmitter synthesis, or a dysbiotic gut microbiome that destabilizes mood through the gut-brain axis. Ketamine opens a window. But that window helps most when the entire system is working with it.

Ketamine

Neuroplasticity, therapeutic window, integration

this area
Gut Reset

Around 90% of serotonin is produced in the gut. Dysbiosis directly limits therapeutic success.

Mold

Mycotoxins generate neuroinflammation and block the healing processes that ketamine is meant to set in motion.

Heavy metals

Mercury and lead disrupt neurotransmitter enzymes. Lower the toxin load, and the window is wider.

Sources

  1. Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49(1):41–50. DOI: 10.1038/s41386-023-01629-w
  2. Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. DOI: 10.1126/science.1190287
  3. Rodolico A et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399. DOI: 10.3389/fpsyt.2024.1325399
  4. Alnefeesi Y et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709.
  5. Nikolin S et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. 2023.
  6. Shiroma PR et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10:206. DOI: 10.1038/s41398-020-00897-0
  7. Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541. DOI: 10.1093/ijnp/pyab023
  8. Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688. DOI: 10.1001/jamapsychiatry.2014.62
  9. Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193–202. DOI: 10.1176/appi.ajp.2020.20050596
  10. Abdallah CG et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of PTSD in veterans. Neuropsychopharmacology. 2022;47(8):1574–1581.
  11. Borgogna NC et al. So how special is ‘special K’? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024.
  12. Almeida K et al. Effectiveness of ketamine for the treatment of PTSD in real world settings. 2024.
  13. Drozdz SJ et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. DOI: 10.2147/JPR.S360733
  14. Sakopoulos S, Todman M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for TRD. Int J Mol Sci. 2025;26(14):6673. DOI: 10.3390/ijms26146673
  15. Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27–38. DOI: 10.1111/j.1360-0443.2011.03576.x
  16. Schak KM et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218.
  17. Singh JB et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry. 2020;7(3):232–235. DOI: 10.1016/S2215-0366(19)30533-4
  18. EMA. Spravato (esketamine): EU marketing authorisation December 2019, extended February 2021. European Medicines Agency.
  19. Anand A et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315–2325. DOI: 10.1056/NEJMoa2302399
  20. Guo X et al. Comparative safety and tolerability of ketamine for treatment-resistant depression: a meta-analysis. Front Pharmacol. 2025. DOI: 10.3389/fphar.2025.1681060

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment